Psoriatic arthritis and spondyloarthritis assessment and management update

Curr Opin Rheumatol. 2013 May;25(3):287-96. doi: 10.1097/BOR.0b013e32835fd8d5.


Purpose of review: There have been numerous recent advances in our understanding about the epidemiology, pathophysiology, classification, assessment, and emerging treatments and treatment paradigms of psoriatic arthritis (PsA) and spondyloarthritis (SpA). This review provides an update on classification, assessment approaches, and treatments for these conditions. This is timely because it is becoming clear that the prevalence of the spondyloarthritides, including PsA, ankylosing spondylitis, and the broader categories of SpA may be present in 1-2% of the general population, more prevalent than rheumatoid arthritis (RA).

Recent findings: There are new classification criteria of axial and peripheral SpA as well as the CASPAR criteria for PsA, a new composite measure for ankylosing spondylitis and axial SpA, the ASDAS, new measures for the heterogeneous clinical domains of PsA, studies of biologic treatments of axial and peripheral SpA, and new drugs beyond anti-tumor necrosis factors for PsA and SpA.

Summary: New criteria, assessment tools, and therapies will aid research, diagnosis, and timely and targeted treatment to quantitated outcomes for PsA and SpA.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Arthritis, Psoriatic / diagnosis
  • Arthritis, Psoriatic / drug therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Interleukin-17 / antagonists & inhibitors
  • Severity of Illness Index
  • Spondylarthritis / diagnosis
  • Spondylarthritis / drug therapy*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors


  • Anti-Inflammatory Agents, Non-Steroidal
  • Immunosuppressive Agents
  • Interleukin-17
  • Tumor Necrosis Factor-alpha